SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss a potential short squeeze, with some highlighting the stock's high short interest and anticipating a breakout above the $60 resistance level. The company's recent launch of a platform for menopause and perimenopause care may be acting as a catalyst, sparking bullish sentiment, while some traders are wary of familiar resistance around the $60 mark.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast is trending as the community highlights its potential for significant growth, citing its small float and EU revenue progress. Bullish investors are actively discussing the stock's undervaluation compared to competitors and anticipating a move towards higher valuations. Positive technical indicators and upcoming Q3 earnings are fueling optimism, with some eyeing a potential short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending due to a surprise $2.1 billion deal with Novo Nordisk, sparking significant investor excitement. The community is focused on the potential for milestone payments and royalties, with many speculating about a potential short squeeze and a re-rating of the stock. Traders are closely watching resistance levels, debating whether to secure profits or hold for further gains based on the news.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending as investors discuss its strategic pivot towards high-performance computing (HPC) and AI, potentially decoupling it from Bitcoin's price action. The community highlights upcoming catalysts like the CEO's X space appearance and the company's potential to reach valuations similar to its competitors. There's also discussion around its growing power capacity and possible data center partnerships, fueling speculation about significant future growth.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

Fueled by speculation around Trump's comments on cooking oil supply chains, Sadot Group Inc. is trending with significant after-hours volatility and high relative volume. The community is actively discussing the low float and potential for a short squeeze, with some debating its long-term value amidst the recent public offering. Others point to the company's financials and potential for a bitcoin treasury strategy as reasons for optimism.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as community members discuss a recent price surge, with some attributing it to increased demand for antimony and potential government contracts. The stock experienced a significant intraday pullback, leading to speculation about short squeezes and future growth potential. Discussions also highlight UAMY's position as a key domestic supplier amid geopolitical tensions related to rare earth minerals.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as the stock experiences volatility, with community members debating potential short squeezes and the impact of partnerships. Some traders express frustration with the stock's performance and management's communication, while others remain optimistic about its long-term potential, citing undervaluation and growth prospects. Discussions also revolve around potential acquisitions and comparisons to competitors within the insurance sector.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending with significant volume as chatter swirls around a potential short squeeze and upcoming presentations at the GITEX Global conference in Dubai. Community members are actively discussing the company's AI-driven drug discovery platform and potential partnerships, with some drawing comparisons to past short squeeze events. Some are speculating about news from Dubai with others suggesting there are big investors buying in.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate the sustainability of its recent surge, with some pointing to potential market manipulation and insider selling. Concerns are rising about a possible offering or short report impacting the stock, contrasting with the continued excitement around quantum computing and the company's long-term potential. The divergence between RGTI and its peers, particularly IONQ, is fueling speculation about the factors driving the stock's price action.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending due to anticipation surrounding its upcoming earnings report and the broader implications for the semiconductor industry, particularly in relation to AI. The community is actively discussing potential revenue and EPS numbers, with some investors buying options in anticipation of a positive earnings surprise. Additionally, there's conversation around the potential for increased AI-related chip demand, and a possible collaboration with Intel.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of <a href="https://stocktwits.com/symbol/ATHE">Alterity Therapeutics</a> soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average.The clinical-stage biotech announced positive Phase 2 results for ATH434, its oral treatment for early-stage multiple system atrophy (MSA)— a rare neurodegenerative disease.Key findings from the 52-week trial:<ul style="list-style-type:square;"><li>50 mg dose: 48% reduction in clinical progression vs. placebo</li><li>75 mg dose: 29% reduction in clinical progression vs. placebo</li></ul>The 50 mg dose reduced iron accumulation in multiple system atrophy-affected brain regions, while the 75 mg dose specifically reduced iron buildup in the globus pallidus.CEO David Stamler said, “Currently, there are no approved treatments that slow the progression of MSA, and these results show ATH434’s targeted iron engagement may truly have a disease-modifying effect.”<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATHE_sentiment_and_message_volume_Jan_30_premarket_df297a4b9a.png" alt="ATHE sentiment and message volume Jan 30 premarket.png" width="1318" height="324"><figcaption>ATHE sentiment and message volume Jan 30 premarket as of 9 am ET | source: Stocktwits</figcaption></figure>Stocktwits message volume for Alterity skyrocketed, hitting ‘extremely high’ levels ahead of Thursday’s&nbsp;opening bell, with sentiment hitting the highest reading in over a year.Some users predicted ATHE could more than triple, stabilizing around $10, while others reiterated their bullish stance on the drug’s market potential.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/602113870</stembedurl><stembedurl>https://stocktwits.com/DaBullRunner/message/602113078</stembedurl>ATHE was among the top three trending tickers on Stocktwits early Thursday.&nbsp;Message volume around the stock on the platform has surged 700% over the past year, during which it has gained 46%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Equity

Alterity Therapeutics Unveils Annual Financial Results

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Limited has released its Preliminary Final Report for the year en...

Alterity Therapeutics Halts Trading for Clinical Update

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Limited (ATH) has requested a trading halt pending an announcemen...

Alterity Therapeutics receives A$3.9M R&D Tax Incentive refund

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

MELBOURNE, AustraliaandSAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company...

Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 25.6%

Alterity Therapeutics Limited (NASDAQ:ATHE  Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 37,800...

Alterity Therapeutics Ltd (ADR) trading halted, news pending

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

- ATH434-201 Trial on Track to Complete in November 2024 - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company dedicated to...

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ATHE
Alterity Therapeutics Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest ATHE News

ATHEAlterity Therapeutics Ltd - ADR